Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral N-Acetyl Cysteine for Prevention of Necrotizing Enterocolitis in Preterm Neonates
NCT06202911Phase 4Active, not recruiting
- Sponsor
- Ain Shams University
- Start
- Jan 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in necrotizing enterocolitis (NEC) comparing Oral NAC with Placebo (2 arms). Primary endpoint: Incidence of Necrotizing Enterocolitis at 10 days. Started Jan 2023; status: active, not recruiting.
02
Drugs
acetylcysteine
03
Conditions
necrotizing enterocolitis (NEC)
Beyond the preview
Go deeper on NCT06202911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06202911.